This study is in progress, not accepting new patients
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
Summary
- Eligibility
- for people ages 5-8 (full criteria)
- Location
- at UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Ayca Erkin-Cakmak (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Ayca Erkin-Cakmak (ucsf)
Dr. Ayca Erkin-Cakmak is a pediatric endocrinologist who cares for children with conditions related to hormonal issues.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Debiopharm International SA
- ID
- NCT06129539
- Phase
- Phase 3 Central Precocious Puberty Research Study
- Study Type
- Interventional
- Participants
- About 56 people participating
- Last Updated